0.0400USD+33.33%Mkt Cap: 373686 USDP/E: —Last update: 2026-05-22
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platfo…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap373.69K USD
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-9.89M USD
Revenue/Share—
Last Price0.0400 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees1
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.01
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.03
EPS (TTM)-1.14
EPS (Forward)-4.04
52W Range
0.010014% of range0.2300
52W High0.2300 USD
52W Low0.0100 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-6424.68%
ROA-254.80%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.57M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.54
Current Ratio—
Quick Ratio—
Book Value/Sh-0.8900 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJan 18, 2019
Splits
Last Split1:20
Split DateFeb 23, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.9.34M
Float—
Insiders0.00%
Institutions0.87%
Short Interest
Short Ratio0.4d
Short % Float1.38%
Short % Out.1.38%
Shares Short79.35K
Short (prev mo.)249.95K
Technical
SMA 500.0560 (-28.6%)
SMA 2000.0730 (-45.2%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)39.90K
Avg Vol (10d)80.53K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—